Abstract
Objectives To estimate the prevalence of maternal substance use during the first 1000 days of children’s lives, to inform planning and resourcing of antenatal screening and substance use in pregnancy services, alongside antenatal and postnatal health, parenting and social support services for pregnant women/new mothers and their babies.
Method This whole-population cohort was assembled from birth registration, perinatal, and hospital data for children born 2008-2017, and their mothers, using data linked for the New South Wales (NSW) Child E-Cohort Project. The primary outcome was maternal substance use and treatment recorded in six health, death, and child protection data sources from the child’s conception to age 2-years (the first 1000 days), including illicit substances, alcohol, opioid-agonist treatment, and misuse of psychoactive medicines or substances.
Results Of 970,470 children born to 625,856 mothers, 3.4% (N=32,647) had ≥1 maternal substance use records in the first 1000 days, including alcohol use (N=13,647; 1.4%) and other drug use (N=23,485; 2.4%). Maternal substance use was recorded during the pregnancy period for 1.2% of children, and from 28-1000 days post-birth for 2.4% of children. Outcome ascertainment was highest from child protection records (N=26,045), followed by mother’s (N=12,956) then children’s hospital records (N=3,826). Child protection records more than doubled the prevalence from health and death records alone (1.4%). Social and health disadvantage was more common among children with maternal substance use.
Conclusion During the first 1000 days of life, 3.4% of NSW children had ≥1 maternal substance use record in health, child protection and death data sources. Child protection data enhances public health intelligence on the burden of maternal substance use among whole-populations of children. Near universal health system contact during pregnancy and birth is an opportunity to initiate early support for maternal substance use and co-occurring health and social disadvantage, to promote child health and development.
What is already known on this topic
Population-level evidence of maternal substance use during the first 1000 days is limited by heterogenous study designs.
Cross-sectional surveys and self-reports illustrate low-level use from 10-18%; studies linking one-four whole-population health datasets provide estimates of 0.2-3% for more harmful use.
What this study adds
Of 970,000 children born 2008-2017 in NSW, Australia, 3.4% had a maternal substance use record during their first 1000 days of life in six linked administrative datasets.
Adding child protection to health and death data more than doubled prevalence estimates.
How this study might affect research, practice or policy
Public health intelligence to inform screening and support services for pregnant women, new mothers and children affected by maternal substance use can be enhanced using child protection data, in addition to health and death data sources.
Near universal health system contact during pregnancy and birth is an opportunity to initiate early support for maternal substance use and co-occurring health and social disadvantage, to promote child health and development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Madeleine Powell was supported by an Australian Government Research Training Program (RTP) Scholarship via the University of New South Wales (UNSW), Sydney, Australia, and a Higher Degree Research scholarship from the National Drug and Alcohol Research Centre (NDARC), UNSW. This work was supported by an NHMRC Clinical Trials and Cohort Studies grant (1187489) awarded to K Falster, R Pilkington, and J Lynch. R Pilkington and Tasnia Ahmed were supported by funds from the NHMRC Clinical Trials and Cohort Studies grant. Rhiannon Pilkington and Tasnia Ahmed were supported by an Australian National Health and Medical Research Council (NHMRC) Clinical Trials and Cohort Studies grant (#1187489). Alys Havard is supported by an NHMRC Ideas grant (#2010778) and the National Drug and Alcohol Research Centre, which is supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. The other authors received no additional funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval: This study was approved by the NSW Population and Health Services Research Ethics Committee (2020/ETH01265), the University of NSW HREC (2020/ETH01265), the Aboriginal Health and Medical Research Council (AH&MRC) of NSW Ethics Committee (1688/20), the NSW Corrective Services Ethics Committee (D20/0886760). The CHeReL operate under strict data security protocols and implements high level physical security measures. Their security protocols are in accordance with the Australian Government Protective Security Policy Framework, the Population Health Research Network Information Governance Framework, and the NHMRC Code for Responsible Conduct of Research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
